In PCOS patients, PPARγ agonists improve insulin sensitivity, hyperinsulinemia, glycemic control, and cardiovascular risk factors like lipid profiles and adiponectin level, but did not affect body weight and body mass index [309,310,311,312,313]. Here, PPARG is linked to polycystic ovary syndrome.